While not extensively utilized in tumor research, IPA-3, serving as a direct non-ATP competitive PAK1 inhibitor, has garnered acclaim in studies pertaining to cellular immune-inflammatory diseases and PAK1-mediated cardiac cell development [128,129]. This evidence concerns the gene PAK1 and neoplasm.